Table 2.
Differences in CD4 cell counts and viral load at end of treatment with triple antiretroviral regimens or dual regimens, and probability of suppressing viral replication
|
CD4 cell count (cells/μ/l)*
|
Viral load (log10 copies/ml)*
|
Viral load (<500 copies/ml)
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Trials | Triple therapy | Dual therapy | Difference (95% CI) | Triple therapy | Dual therapy | Difference (95% CI) | Triple therapy† | Dual therapy† | Odds ratio (95% CI) |
|
Protease inhibitor based regimens
| |||||||||
| AIDs Clinical Trials Groups: | |||||||||
| 229 | 157 | 170 | −13 (−19 to −7) | 4.40 | 4.52 | −0.12 (−0.44 to 0.20) | NR | NR | — |
| 32021 | 208 | 127 | 81 (53 to 109) | 2.90 | 4.00 | −1.10 (−1.55 to −0.65) | 42/93 | 6/97 | 12.5 (5.0 to 31.4) |
| Merck 03520 | 219 | 190 | 29 (−4 to 62) | 2.87 | 3.81 | −0.94 (−1.24 to −0.64) | 28/33 | 0/33 | 347 (18.4 to 6500) |
| RTV Study Group22 | 68 | 20 | 48 (44 to 52) | 4.80 | 5.70 | −0.90 (−1.12 to −0.68) | NR | NR | — |
| Merck 03927 | 114 | 24 | 90 (77 to 103) | 3.31 | 4.48 | −1.17 (−1.36 to −0.98) | 60/108 | 0/105 | 263 (15.9 to 4300) |
| Spanish Earth-128 | 901 | 808 | 93 (30 to 156) | 2.45 | 2.79 | −0.34 (−0.54 to −0.14) | 30/33 | 11/33 | 20.0 (5.0 to 80.3) |
| PISCES31 | 269 | 234 | 35 (24 to 46) | NR | NR | — | NR | NR | — |
| Combined‡ | — | — | 49 (18 to 80); P<0.0001 | — | — | −0.76 (−1.11 to −0.41); P<0.0001 | — | — | 42 (9.0 to 198); P=0.026 |
|
Non-nucleoside reverse transcriptase based regimens
| |||||||||
| AIDS Clinical Trials Group: | |||||||||
| 24123 | 115 | 93 | 22 (3 to 41) | 6.80 | 6.06 | 0.74 (0.45 to 1.03) | NR | NR | — |
| 193A25 | 18 | 14 | 4 (0.6 to 7) | 4.42 | 4.81 | −0.39 (−0.60 to −0.18) | NR | NR | — |
| Study 0021 Pt 232 | NR | NR | — | NR | NR | — | 25/124 | 7/124 | 4.2 (1.8 to 10.2) |
| INCAS26 | 526 | 477 | 49 (−8 to 106) | 1.94 | 3.37 | −1.43 (−2.30 to −0.56) | 20/51 | 8/53 | 3.6 (1.4 to 9.3) |
| ISS 04729 | NR | NR | — | NR | NR | — | 15/32 | 3/36 | 9.7 (2.5 to 38.2) |
| AIDS Clinical Trials Group 26130 | 359 | 328 | 31 (−2 to 64) | 3.74 | 3.78 | −0.04 (−0.42 to 0.34) | 13/61 | 8/60 | 1.8 (0.7 to 4.6) |
| Study 13C33 | NR | NR | — | NR | NR | — | 34/172 | 7/173 | 5.8 (2.5 to 13.6) |
| Combined‡ | — | — | 18 (0.1 to 35); P=0.044 | — | — | −0.20 (−0.89 to 0.50); P<0.0001 | — | — | 4.1 (2.5 to 6.7); P=0.264 |
| Indirect comparison | — | — | 25 (−17 to 68) | — | — | −0.59 (−1.32 to 0.15) | — | — | 6 (2.2 to 16.6) |
NR=not reported.
*
Mean values used if median not available.
†
Number of participants with viral load <500 copies/ml (total number of participants); 0.5 added for zero cell counts.
‡
P values from test of heterogeneity.